From: Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S − 1 therapy
Decreased dosage level
Irinotecan
Ramucirumab
-1
120 mg/ m2
6 mg/kg
-2
100 mg/m2
5 mg/kg
-3
80 mg/m2
0 mg/m2